NEO: NeoGenomics Laboratories Price to Sales
NeoGenomics, Inc. (NEO) is upgrading its equipment to accelerate diagnostics without operational downtime. Management is implementing a process optimization strategy to drive margin growth and foster partnerships with pharmaceutical behemoths. The company's current P/S ratio illustrates the business valuation trend, where the 2.70 metric determines this level. The high status of its research and generous bonuses enable the recruitment of leading oncology specialists, as this chart confirms.
Analytical breakdowns for NeoGenomics Laboratories (NEO)
- market value and analyst target forecast:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio NeoGenomics, Inc.|NEO - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient NeoGenomics Corp|NEO - Company Aggregate Debts|Debt to Book Value NeoGenomics Laboratories|NEO - Company Long-Term Debt|Short-Term Debt Volume NeoGenomics|Intermediate Coverage Ratio neogenomics.com
- net income and valuation multiples indicators:
NEO - Net Profit|Company Profit Forecast NeoGenomics, Inc.|NEO - Price to Earnings Ratio|Price to Future Earnings Ratio NeoGenomics Inc|NEO - PEG Multiple|Enterprise Value to EBITDA Ratio NeoGenomics Laboratories|NEO - Operating profit before deduction of amortization|Net earnings per share for the last four quarters NeoGenomics|NEO - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months neogenomics.com|NEO - Earnings growth in current year|Expected net earnings per share growth next year NeoGenomics, Inc.
- total revenue and sales volume data:
General company analysis:NEO (neogenomics.com)
To filter for high-quality assets, investors utilize a comparative analysis of market value and actual cash flows. This price-to-sales ratio compares the market capitalization of NeoGenomics, Inc. (NEO) with its annual sales volume, allowing for an assessment of the extent to which the market is overpaying for the company's exceptional authority in cancer diagnostics and its unique portfolio of genetic tests, as clearly reflected in the chart's price action.
Competitors of NeoGenomics, Inc.
linde.com (LIN) - Price-to-Revenue Multiple|P/S Multiple APD (Air Products and Chemicals)|DuPont de Nemours (DD) - Price to Sales|IP - Price-to-Revenue Ratio|PPG (PPG Industries, Inc.) - Market Cap to Revenue Ratio|Dow Inc. (DOW) - Price-to-Revenue Ratio|Price to Sales lyondellbasell.com (LYB)|Price-to-Revenue Ratio International Flavors & Fragrances Inc|Market Cap to Revenue RPM International Inc (RPM)|P/S Multiple ENTG|Price-to-Revenue Coefficient Suzano Group|P/S Multiple WLK (Westlake Corporation)|ALB - Market Cap to Revenue|ICL - Price-to-Revenue Ratio|Price-to-Revenue Coefficient NewMarket Corp NEU|EMN (Eastman Chemical Corp) - Market Cap to Revenue|Axalta Corp - Market Capitalization-to-Revenue Ratio|ESI (Element Solutions Inc) - P/S Multiple|sqm.com (SQM) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Celanese (CE)|Sensient Technologies Corporation - Market Cap to Revenue Ratio|P/S Multiple CBT (Cabot Microelectronics)|HWKN - Market Cap to Revenue|AVNT: Market Cap to Revenue|Price-to-Revenue Coefficient hbfuller.com FUL|Methanex (MEOH) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio WDFC|CC (Chemours Corp) - P/S Multiple|Price to Sales Quaker Chemical Corp. KWR|Price-to-Revenue Ratio PureCycle Technologies (PCT)|ASH - Price to Sales|P/S Multiple NGVT (Ingevity)|IOSP - Market Cap to Revenue|Minerals Tech - P/S Multiple|Market Capitalization-to-Revenue Ratio DQ (Daqo Solar)|SLVM: P/S Multiple|Price to Sales huntsman.com (HUN)|Price-to-Revenue Ratio Albany International Corp.|Market Cap to Revenue Calumet Specialty Products Partners, L.P. (CLMT)|P/S Multiple ROG|Price-to-Revenue Coefficient Stepan Chemical|Price-to-Revenue Ratio Ecovyst Inc. ECVT|Price-to-Revenue Coefficient rexamerican.com (REX)|ASPI: Market Cap to Revenue|Tronox Holdings - Market Cap to Sales Volume|Ferroglobe Corp (GSM) - Price-to-Revenue Ratio|Westlake Partners - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CMP|Price to Sales kronostio2.com KRO|Price-to-Revenue Ratio Mativ (MATV)|LSB Industries Inc - Market Cap to Revenue Ratio|P/S Multiple BAK (Braskem Group)|Koppers Corp (KOP) - Price to Sales|ASIX - Price-to-Revenue Ratio|Price to Sales orioncarbons.com|RYAM: P/S Multiple|Price-to-Revenue Multiple Aduro Clean Tech ADUR|MAGN (Magnera Inc.) - P/S Multiple|Price to Sales Clearwater Paper Corp. CLW|Price-to-Revenue Ratio Tredegar Corporation (TG)|coremt.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio FutureFuel FF|Flexible Solutions International Inc. (FSI) - Price to Sales|ALTO - Price-to-Revenue Ratio|5E Advanced Materials (FEAM) - Market Cap to Revenue|TSE: P/S Multiple|ORGN - Price-to-Revenue Coefficient|NTIC (Northern Technologies International) - P/S Multiple|Market Cap to Revenue LanzaTech Global (LNZA)|Price-to-Revenue Ratio J-Star Holding Co Ltd (YMAT)|Price-to-Revenue Coefficient newerahelium.com|Bolt Projects Holdings - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio BGLC|Gulf Resources - P/S Multiple|Price-to-Revenue Coefficient CN Energy Group. Inc. CNEY|arcadiumlithium.com (ALTM) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio DNMR|GLT (Glatfelter Corp) - P/S Multiple|Market Cap to Revenue Graphex (GRFX)|Market Cap to Revenue SLCA (U.S. Silica)|Price-to-Revenue Coefficient Invizyne Technologies Inc
